z-logo
open-access-imgOpen Access
High-level production of replication-defective human immunodeficiency type 1 virus vector particles using helper-dependent adenovirus vectors
Author(s) -
Yani Hu,
Kaitlin C. O’Boyle,
Donna Palmer,
Philip Ng,
Richard E. Sutton
Publication year - 2015
Publication title -
molecular therapy — methods and clinical development
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.285
H-Index - 32
ISSN - 2329-0501
DOI - 10.1038/mtm.2015.4
Subject(s) - vector (molecular biology) , viral vector , virology , plasmid , lentivirus , transfection , genetic enhancement , transduction (biophysics) , helper virus , biology , virus , titer , human immunodeficiency virus (hiv) , expression vector , viral replication , gene , recombinant dna , genetics , viral disease , biochemistry
Gene transfer vectors based upon human immunodeficiency virus type 1 (HIV) are widely used in bench research applications and increasingly in clinical investigations, both to introduce novel genes but also to reduce expression of unwanted genes of the host and pathogen. At present, the vast majority of HIV-based vector supernatants are produced in 293T cells by cotransfection of up to five DNA plasmids, which is subject to variability and difficult to scale. Here we report the development of a HIV-based vector production system that utilizes helper-dependent adenovirus (HDAd). All necessary HIV vector components were inserted into one or more HDAds, which were then amplified to very high titers of â¼1013 vp/ml. These were then used to transduce 293-based cells to produce HIV-based vector supernatants, and resultant VSV G-pseudotyped lentiviral vector (LV) titers and total IU were 10- to 30-fold higher, compared to plasmid transfection. Optimization of HIV-based vector production depended upon maximizing expression of all HIV vector components from HDAd. Supernatants contained trace amounts of HDAd but were free of replication-competent lentivirus. This production method should be applicable to other retroviral vector systems. Scalable production of HIV-based vectors using this two-step procedure should facilitate their clinical advancement

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom